Pulse Biosciences (PLSE) Cash & Equivalents (2015 - 2025)

Pulse Biosciences has reported Cash & Equivalents for 11 years, with the latest figure at $80.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 31.6% year-over-year to $80.7 million; the trailing twelve-month figure through Dec 2025 stood at $80.7 million (down 31.6% YoY), and the FY2025 full-year result was $80.7 million, down 31.6% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $80.7 million, down from $95.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $119.3 million in Q1 2025, with the low at $12.7 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $60.4 million, with a median of $54.3 million recorded in 2022.
• Year-over-year, Cash & Equivalents soared 661.48% in 2021 and slumped 78.83% in 2022.
• Tracing PLSE's Cash & Equivalents over 5 years: stood at $44.4 million in 2021, then jumped by 30.67% to $58.0 million in 2022, then decreased by 23.47% to $44.4 million in 2023, then surged by 166.06% to $118.0 million in 2024, then tumbled by 31.6% to $80.7 million in 2025.
• The last three Cash & Equivalents figures came in at $80.7 million (Q4 2025), $95.2 million (Q3 2025), and $106.3 million (Q2 2025), per Business Quant data.

Peer Comparison